Answers are grounded in this paper and cite their sources.
Background and Objectives Traditional preventive treatments for migraine have limitations (e.g., efficacy, adverse events [AEs], contraindications, and interactions). The aim of this study was to evaluate the efficacy and safety of 2 rimegepant dosing regimens relative to placebo as preventive treatment for episodic migraine. Methods This was a phase 4, randomized, placebo-controlled study. Adults with a ≥1-year history of episodic migraine (with or without aura) and 4–14 migraine attacks/month were enrolled from outpatient/research sites in 10 countries. After a 28-day observation phase, participants were randomly assigned to placebo once daily, rimegepant 75 mg every other day/alternating placebo, or rimegepant 75 mg once daily for 12-weeks of double-blind treatment. The primary end point was mean reduction from the observation phase in monthly migraine days over the entire 12-week double-blind phase analyzed using linear mixed effects modeling. Hierarchical testing was used for key secondary end points to control type I error. Safety assessments included AEs. Results Participants (n = 692; median age 44.0 years, 86.7% female) were treated double blind with rimegepant every other day (n = 232), rimegepant once daily (n = 229), or placebo (n = 231). The primary end point was met for both rimegepant dosing regimens, with significantly greater reductions from the observation phase in monthly migraine days over the entire double-blind phase vs placebo (least squares mean change difference [97.5% CI]) for rimegepant every other day (−0.6 [−1.22 to −0.01], p = 0.0220) and rimegepant once daily (−1.8 [−2.35 to −1.19], p < 0.0001). All 5 key secondary end points were significant vs placebo for rimegepant once daily ( p < 0.0001), while for rimegepant every other day, the first key secondary end point in the hierarchy was not significant vs placebo. Most AEs were mild or moderate. Discussion Both rimegepant dosing regimens were superior to placebo for the preventive treatment of migraine and were well tolerated. This study demonstrates the efficacy and safety of rimegepant 75 mg QD in a double-blind study. The study was not designed to directly compare the rimegepant EOD and QD dosing regimens. Trial Registration Information ClinicalTrials.gov NCT05217927 ( clinicaltrials.gov/study/NCT05217927 ); registered January 20, 2022; first enrollment March 4, 2022. Classification of Evidence This study provides Class I evidence that in adults with more than 1-year history of episodic migraine and 4–14 migraine attacks/month, both rimegepant 75 mg every other day and rimegepant 75 mg daily were superior to placebo in reducing monthly migraine days up to 12 weeks of follow-up.
No takes yet. Share an insight, caveat, or question.
Goadsby et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: